TY  - JOUR
AU  - Xuan, J
AU  - Pearson, RB
AU  - Sanij, E
Y2  - 2020/11/27
Y1  - 2020/09/02
SN  - 2372-3556
UR  - http://hdl.handle.net/11343/252553
AB  - Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
LA  - English
PB  - TAYLOR & FRANCIS INC
T1  - CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
DO  - 10.1080/23723556.2020.1805256
IS  - Molecular & cellular oncology
VL  - 7
IS  - 6
L1  - /bitstream/handle/11343/252553/CX%205461%20can%20destabilize%20replication%20forks%20in%20PARP%20inhibitor%20resistant%20models%20of%20ovarian%20cancer.pdf?sequence=1&isAllowed=y
ER  -